8-K: Coherus BioSciences Reports Strong Q2 2024 Results Driven by UDENYCA Sales and Strategic Divestitures

Coherus BioSciences announced positive second quarter 2024 financial results, highlighted by a 60% increase in UDENYCA sales compared to the same period last year and the appointment of a new Chief Financial Officer.

Summary

• Coherus BioSciences reported a net revenue of $65.0 million for the second quarter of 2024, which includes $50.9 million from UDENYCA sales, $3.8 million from LOQTORZI sales, and $3.8 million from YUSIMRY sales before its divestiture.
• UDENYCA sales increased by 19% compared to the previous quarter and 60% compared to the same quarter last year, with a 29% market share.
• LOQTORZI, launched in January 2024, generated $3.8 million in sales and is now available in all 33 National Comprehensive Cancer Network institutions.
• The company divested YUSIMRY for $40.0 million and received a $6.3 million upfront payment for out-licensing LOQTORZI in Canada.
• The company reported a net loss of $12.9 million for the quarter, an improvement from a $42.9 million loss in the same period last year.
• For the first half of 2024, Coherus reported a net income of $90.0 million, compared to a net loss of $118.6 million for the first half of 2023.
• The company's cash, cash equivalents, and investments totaled $159.2 million as of June 30, 2024.
• Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, strategic divestitures, and improved financial performance. The appointment of a new CFO adds to the positive sentiment. However, the company still faces risks and challenges in the competitive biopharmaceutical market.

Positives

• UDENYCA sales and market share are significantly increasing.
• LOQTORZI is showing promising early sales and has achieved broad market access.
• Strategic divestitures have generated substantial gains and improved the company's financial position.
• The company has significantly reduced its net loss and achieved net income for the first half of 2024.
• The company has strengthened its financial position by reducing debt and increasing cash reserves.
• The company is advancing its immuno-oncology pipeline with multiple clinical trials underway.
• The appointment of a permanent CFO provides stability and leadership.

Negatives

• The company reported a net loss of $12.9 million for the second quarter of 2024.
• Cost of goods sold increased due to higher unit volumes and a contract change fee.
• Research and development expenses remain significant, although they have decreased compared to the previous year.
• The company is still reliant on a small number of products for the majority of its revenue.

Risks

• The company faces risks inherent in the clinical drug development process.
• There are risks related to the company's competitive position and the regulatory approval process.
• The company's future financial performance is subject to a number of risks and uncertainties.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ significantly.

Future Outlook

Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million and expects long-term revenue growth from LOQTORZI.

Management Comments

• Denny Lanfear, Coherus Chairman and Chief Executive Officer, stated that the first half of 2024 has been a period of disciplined execution of their strategy.
• Bryan McMichael, Coherus Chief Financial Officer, expressed confidence in the company's future and looks forward to executing the company's strategy.

Industry Context

The company's focus on oncology and immuno-oncology aligns with current industry trends, with a growing emphasis on targeted therapies and biosimilars. The successful launch of LOQTORZI and the growth of UDENYCA position Coherus as a key player in the oncology market.

Comparison to Industry Standards

• Coherus's UDENYCA market share of 29% is competitive with other biosimilars in the pegfilgrastim market, such as those from Amgen and Sandoz.
• The company's LOQTORZI launch is comparable to other novel oncology drug launches, with a focus on establishing market access and driving patient uptake.
• The divestiture of non-core assets like CIMERLI and YUSIMRY is a common strategy for biopharmaceutical companies to focus on core competencies and improve financial performance, similar to moves by companies like Teva and Mylan.
• The company's R&D spending is in line with other companies developing novel immuno-oncology therapies, such as Iovance Biotherapeutics and Adaptimmune.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and strategic focus on oncology.
• Employees may experience changes due to the company's restructuring and focus on oncology.
• Patients will benefit from the continued development and commercialization of innovative cancer therapies.
• Customers will have access to a broader range of oncology treatments.
• Suppliers may see changes in demand based on the company's product portfolio.

Next Steps

• Continue enrollment in expansion cohorts for the CHS-114 Phase 1 study.
• Initiate a Phase 2 study for casdozokitug in Q4 2024.
• Initiate a Phase 1 study for CHS-1000 in the coming months.

Key Dates

Keywords

UDENYCA, LOQTORZI, biosimilar, oncology, immunotherapy, financial results, clinical trials, biopharmaceutical, divestiture, CFO